I just can't see how the share price wouldn't spike on approval, particularly with the short squeeze as a result.
I suspect shorters are there more to profit from rejection, than hoping that approval won't lead to a price rise. If CUV get access to the US market then the current share price will look pretty cheap in a year or so once they hit full stride (probably less than that, given they'll be ready to pull the sales trigger immediately, and will likely have plenty of doctors/patients who are already aware of the product).
I just can't see how the share price wouldn't spike on approval,...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.040(0.29%) |
Mkt cap ! $701.0M | |||
| Open | High | Low | Value | Volume |
| $14.10 | $14.20 | $13.97 | $452.4K | 32.15K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $14.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.12 | 66 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |